COAG (Hemab Therapeutics Holdings) Research & Development: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $46.54
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings Research & Development?

Hemab Therapeutics Holdings COAG +3.48% 11 Research & Development is $ Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hemab Therapeutics Holdings's Research & Development for the six months ended in Dec. 2025 was $59.63 Mil. Hemab Therapeutics Holdings does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

Hemab Therapeutics Holdings  (NAS:COAG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hemab Therapeutics Holdings Research & Development Related Terms

Hemab Therapeutics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Research & Development Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Research & Development
41.41 59.63

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
Research & Development 41.41 59.63
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $ Mil mean?
Hemab Therapeutics Holdings (COAG) has a Research & Development of $ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Hemab Therapeutics Holdings and its competitors.
Is Hemab Therapeutics Holdings' Research & Development too high?
Hemab Therapeutics Holdings' current Research & Development is $ Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Research & Development compare to ZLAB and SLS?
Hemab Therapeutics Holdings' Research & Development of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hemab Therapeutics Holdings and its competitors. Hemab Therapeutics Holdings's current Research & Development is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Research & Development of $ Mil. The current Research & Development is $ Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Research & Development is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.54
Price